RK Capital Management LLC purchased a new position in Teligent, Inc. (NASDAQ:TLGT) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm purchased 500,617 shares of the company’s stock, valued at approximately $4,581,000. RK Capital Management LLC owned about 0.94% of Teligent as of its most recent SEC filing.
Several other large investors also recently bought and sold shares of the company. Russell Investments Group Ltd. raised its stake in Teligent by 124.1% during the 2nd quarter. Russell Investments Group Ltd. now owns 1,043,046 shares of the company’s stock worth $9,544,000 after buying an additional 577,635 shares during the period. Vanguard Group Inc. raised its stake in Teligent by 10.4% during the 1st quarter. Vanguard Group Inc. now owns 1,976,891 shares of the company’s stock worth $15,440,000 after buying an additional 185,624 shares during the period. Timpani Capital Management LLC acquired a new stake in Teligent during the 2nd quarter worth $1,692,000. Icon Advisers Inc. Co. acquired a new stake in Teligent during the 2nd quarter worth $754,000. Finally, Skandinaviska Enskilda Banken AB publ acquired a new stake in Teligent during the 1st quarter worth $612,000. Institutional investors and hedge funds own 66.81% of the company’s stock.
Teligent, Inc. (TLGT) traded up 5.74% during mid-day trading on Friday, hitting $7.19. The company’s stock had a trading volume of 1,079,949 shares. The firm’s market cap is $383.88 million. Teligent, Inc. has a 52-week low of $5.75 and a 52-week high of $8.06. The firm has a 50 day moving average of $6.91 and a 200-day moving average of $6.97.
Teligent (NASDAQ:TLGT) last issued its quarterly earnings results on Tuesday, August 8th. The company reported ($0.02) EPS for the quarter, missing the Zacks’ consensus estimate of $0.02 by ($0.04). The firm had revenue of $18.40 million for the quarter, compared to the consensus estimate of $20.11 million. Teligent had a negative net margin of 11.36% and a positive return on equity of 1.49%. The business’s revenue was up 7.4% compared to the same quarter last year. During the same period last year, the company posted $0.02 EPS. On average, equities research analysts expect that Teligent, Inc. will post $0.07 EPS for the current fiscal year.
TLGT has been the topic of several research analyst reports. Zacks Investment Research downgraded Teligent from a “hold” rating to a “sell” rating in a research note on Thursday, July 6th. Deutsche Bank AG reaffirmed a “hold” rating and set a $9.00 price objective (up previously from $8.00) on shares of Teligent in a research note on Monday, July 17th. BidaskClub downgraded Teligent from a “hold” rating to a “sell” rating in a research note on Monday, July 24th. ValuEngine downgraded Teligent from a “hold” rating to a “sell” rating in a research note on Tuesday, July 25th. Finally, Canaccord Genuity initiated coverage on Teligent in a research note on Monday, July 31st. They set a “buy” rating and a $11.00 price objective on the stock. Three equities research analysts have rated the stock with a sell rating, one has issued a hold rating and two have given a buy rating to the company’s stock. Teligent has a consensus rating of “Hold” and an average target price of $9.00.
Teligent Company Profile
Teligent, Inc is a specialty generic pharmaceutical company. Under the Company’s own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. In the United States it marketed 16 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2016.
Want to see what other hedge funds are holding TLGT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teligent, Inc. (NASDAQ:TLGT).
Receive News & Ratings for Teligent Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teligent Inc. and related companies with MarketBeat.com's FREE daily email newsletter.